DISEASE CHARACTERISTICS: - Histologically confirmed glioblastoma multiforme (GBM) (WHO grade IV) by central pathology review - Gliosarcoma allowed - Tumor must have a supratentorial component - Diagnosis must have been made by surgical excision, either partial or complete excision, within the past 5 weeks - Stereotactic biopsy or Cavitron ultrasonic aspirator-derived tissue are not allowed - Tumor tissue available for correlative studies (phase II only) - Patients must have ≥ 1 block of tissue; if a block cannot be submitted, two tissue specimens punched with a skin punch (2 mm diameter) from the tissue block containing the tumor may be submitted - No recurrent or multifocal malignant glioma - No metastases detected below the tentorium or beyond the cranial vault PATIENT CHARACTERISTICS: - Karnofsky performance status 70-100% - ANC ≥ 1,800/mm^3 - Platelet count ≥ 100,000/mm^3 - Hemoglobin ≥ 10.0 g/dL (transfusion or other intervention allowed) - PT/INR ≤ 1.5 - BUN ≤ 30 mg/dL - Serum creatinine ≤ 1.5 times upper limit of normal (ULN) - Bilirubin ≤ 1.5 times normal - ALT and AST ≤ 2.5 times normal - Fasting serum cholesterol ≤ 300 mg/dL OR ≤ 7.75 mmol/L AND fasting triglycerides ≤ 2.5 times ULN (if one or both of these thresholds are exceeded, patients are eligible only after initiation of appropriate lipid-lowering medication) - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - No other invasive malignancy within the past 3 years except for nonmelanoma skin cancer or carcinoma in situ of the breast, oral cavity, or cervix - No severe, active co-morbidity, defined as follows: - NYHA class III-IV symptomatic congestive heart failure - Unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction within the past 6 months, serious uncontrolled cardiac arrhythmia, or any other clinically significant cardiac disease - Severely impaired lung function, defined as spirometry and DLCO that is 50% of the normal predicted value and/or oxygen saturation that is ≤ 88% at rest on room air - Uncontrolled diabetes, defined as fasting serum glucose > 1.5 times ULN - Active (acute or chronic) or uncontrolled severe infections requiring IV antibiotics - Liver disease such as cirrhosis, chronic active hepatitis, or chronic persistent hepatitis - AIDS based upon current Centers for Disease Control and Prevention definition or known HIV seropositivity (HIV testing is not required for study entry) - Active connective tissue disorders such as lupus erythematosus or scleroderma that, in the opinion of the treating physician, may put the patient at high risk for radiation toxicity - Other major medical illness or psychiatric impairment that, in the investigator's opinion, will prevent administration or completion of study treatment - No impaired gastrointestinal (GI) function or GI disease that may significantly alter the absorption of everolimus (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection) - No history of deep vein thrombosis or pulmonary embolism - No prior allergic reaction to temozolomide - No known hypersensitivity to mTOR inhibitors (e.g., sirolimus, temsirolimus, everolimus) or to their excipients PRIOR CONCURRENT THERAPY: - See Disease Characteristics - Recovered from the effects of surgery, postoperative infection, and other complications - No prior temozolomide - No prior mTOR inhibitor (e.g., sirolimus, temsirolimus, everolimus) - No prior Gliadel wafers or any other intratumoral or intracavitary treatment - No prior radiotherapy to the head or neck (except for T1 glottic cancer) resulting in overlap of radiotherapy fields - No prior chemotherapy or radiosensitizers for cancer of the head and neck region - Prior chemotherapy for a different cancer is allowed - No prior radiotherapy or chemotherapy for GBM - No prior or concurrent treatment on any other therapeutic clinical study - At least 14 days since prior and no concurrent enzyme-inducing anti-epileptic drugs - Concurrent anticoagulation allowed provided target INR ≤ 1.5 AND patient is on a stable dose of warfarin or low molecular weight heparin for > 2 weeks